Background: The emergence of bla KPC -containing Klebsiella pneumoniae (KPC-Kp) isolates is attracting significant attention. Outbreaks in the Eastern USA have created serious treatment and infection control problems. A comparative multi-institutional analysis of these strains has not yet been performed.
Introduction
The emergence of KPC carbapenemases in strains of Enterobacteriaceae and Pseudomonas aeruginosa is attracting significant attention. In current surveys, Klebsiella pneumoniae is the most common pathogen harbouring bla KPC genes. 1 -5 Additionally, bla KPC -containing K. pneumoniae (KPC-Kp) isolates are becoming endemic in certain hospitals and are responsible for increasing numbers of outbreaks in several healthcare facilities located in the Eastern USA, 6 -8 Israel 9,10 and Greece. 11, 12 Recently, sporadic KPC-Kp isolates were detected in Central and South America, 5, 13, 14 the Far East 15 -17 and Europe. 18 -20 In the clinical laboratory, KPC-Kp isolates demonstrate resistance or reduced susceptibility to all b-lactams as well as many other classes of antimicrobial agents (i.e. fluoroquinolones, aminoglycosides and sometimes polymyxins). 4, 7, 21 Therefore, the emergence and spread of this multidrug-resistant (MDR) phenotype has created serious treatment and infection control problems. 22, 23 Detection of KPC-mediated carbapenem resistance in these isolates also poses a significant challenge for many clinical laboratories. 21, 24, 25 Studies that examine the clonal relationship of large collections of KPC-Kp isolates from geographically separate institutions are still lacking. Earlier efforts investigating the clonal relatedness of KPC-Kp used isolates that were obtained from single hospitals or from the same geographic region (e.g. Tel Aviv and New York City). 6 -10 Moreover, previous analyses were performed using PFGE, ribotyping or randomly amplified DNA. 6 -9 The DiversiLab TM Strain Typing System, (Bacterial BarCodes, bioMérieux, Athens, GA, USA) is a semi-automated rep-PCR method able to analyse large numbers of isolates rapidly. 26 Despite the literature regarding the use of the rep-PCR for epidemiological studies, the DiversiLab TM System has not yet been tested for K. pneumoniae as well as for KPC-Kp isolates.
Little is known regarding the presence of other b-lactamases or the genetic environment of isolates possessing bla KPC genes. Moland et al. 27 reported a unique KPC-Kp strain producing at least eight different b-lactamases. Other studies have discovered a limited number of bla genes in addition to bla KPC . 7, 10, 15, 24, 28, 29 In a study performed by Bradford et al., 29 the b-lactamases possessed by 18 KPC-Kp isolates were characterized by PCR and cloning. Although three strains possessed two TEM-type enzymes, only one SHV-type b-lactamase was found in each of the 18 strains.
Taken together, the above considerations compelled us to characterize the b-lactamase background of KPC-Kp isolates from several institutions in order to: (i) understand the evolution of the molecular epidemiology of KPC-Kp in the Eastern USA; (ii) assess the in vitro efficacy of antibiotic combinations (i.e. b-lactam/b-lactamase inhibitor combinations); and (iii) compare the ability of DiversiLab TM Strain Typing System versus PFGE to characterize KPC-Kp isolates. To these ends, we determined the b-lactam resistance phenotypes, b-lactamase genotypes and clonality of a large set of KPC-Kp isolates recently collected from five major healthcare institutions located in the Eastern USA. We discovered that KPC-Kp isolates frequently belong to a single genotype and possess a complex b-lactamase background, in the context of significant resistance to penicillins, cephalosporins, carbapenems and b-lactam/b-lactamase inhibitor combinations, limiting the choices available for antibiotic therapy.
Materials and methods

Clinical isolates
Forty-two KPC-Kp strains collected during a previous study were analysed. 30 Isolates were detected from January 2006 to October 2007 at Mount Sinai Medical Center in New York City (MSMCNY, n¼ 24), University of Pittsburgh Medical Center (UPMC, n¼ 4) and three Cleveland institutions including University Hospitals Case Medical Center (UHCMC, n¼ 2), Cleveland Clinic (CC, n¼ 9) and Louis Stokes Veterans Affairs Medical Center (LSVAMC, n¼ 3).
PCR and sequencing of b-lactamase genes
Specific primers were used to amplify and sequence the bla KPC genes [ Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. KPC-Kp isolates were further investigated by PCR amplification to detect other resistance determinants, including those for other carbapenemases, bla ESBL genes (where ESBL stands for extended-spectrum b-lactamase) and bla AmpC genes. The complete list of genes investigated and the corresponding set of primers used for PCR and DNA sequencing analysis are reported in Table S1 .
DNA was obtained by suspending two to three colonies of each test isolate grown on MacConkey agar plates in 500 mL of nucleasefree water (UBS Corporation, Cleveland, OH, USA) and heating at 908C for 10 min using a dry bath incubator. Samples were spun at 10 000 rpm for 10 min and the resulting supernatant was diluted 1:10 with nuclease-free water. These samples were used as the bacterial DNA template for PCR assays. Amplification reactions were performed using the high-fidelity rTth DNA Polymerase XL (GeneAmp XL PCR Kit; Applied Biosystems, Foster City, CA, USA). Temperature cycling conditions included an initial denaturation at 948C for 1 min followed by 30 cycles of 948C for 30 s, annealing for 30 s (see Table S1 for the temperature of each primer set), with an extension at 728C for 30 s. Cycling was followed by a final extension at 728C for 10 min. Samples were incubated in the PTC-225 Peltier Thermal Cycler (MJ Research, Waltham, MA, USA). Reaction mixture (5 mL) containing the PCR product was mixed with 2 mL of UltraClean Gel Dye (Mo Bio Laboratories Inc., Carlsbad, CA, USA) and analysed by electrophoresis in a 1% Ultrapure MB Grade agarose gel (USB Corporation).
The remaining amplified product (20 mL) was purified using Exonuclease I and Shrimp Alkaline Phosphatase before DNA sequencing, according to the manufacturer's instructions (ExoSAP-IT protocol; USB Corporation). Samples were incubated at 378C for 30 min, at 458C for 15 min and at 808C for 15 min to degrade the unincorporated primers and nucleotides. Sequencing reactions were performed using BigDye v1.1 Sequencing Kits (Applied Biosystems, Foster City, CA, USA) and sequence data were acquired on a 3730xl DNA Analyzer (Applied Biosystems). DNA traces were interpreted by Lasergene 7.2 (DNASTAR, Madison, WI, USA). The final b-lactamase amino acid sequences were determined using the ExPASy Proteomics Server (http://ca.expasy.org) and compared with those previously described (http://www.lahey.org/studies/webt.htm).
Cloning and sequencing of multiple b-lactamase alleles
In cases where multiple alleles were suspected (i.e. double 'spikes' in the DNA sequencing traces at a single location), a new PCR product for each isolate was obtained as described above; however, the reactions were limited to 18 cycles of amplification. The product was purified using the QIAquick PCR Purification Kit (Qiagen Sciences, Valencia, CA, USA) and subsequently cloned into a pCR-XL-TOPO vector, according to the manufacturer's instructions (TOPO XL PCR Cloning Kit; Invitrogen Corporation, Carlsbad, CA, USA). Plasmids were electroporated into competent ElectroMAX Escherichia coli DH10B cells (Invitrogen Corporation) and selected on Luria-Bertani (LB) agar containing kanamycin sulphate (50 mg/L; Invitrogen Corporation). Ten random colonies for each cloned PCR product were selected and cultures were grown overnight at 378C in 3 mL of LB broth containing kanamycin sulphate (50 mg/L). Plasmids were isolated using the Wizard Plus Miniprep Kit (Promega, Madison, WI, USA). Direct sequencing of the plasmid preparations was done using the primers previously listed (Table S1 ). Furthermore, specific primers for the TOPO vector were also used (M13-forward, 5
0 -GTAAAACGACGGCCAG-3 0 ; M13-reverse, 5
0 -CAGGAAACAGCTATGAC-3 0 ). Three E. coli DH10B isolates containing bla SHV-11 (VA-401-t5), bla SHV-12 (VA-389-t4) or bla TEM-1 (VA-402-t3) cloned into the pCR-XL-TOPO vector and one bla KPC-2 -containing K. pneumoniae strain (VA-361) were used as controls to test the reliability of the above cloning method.
Antimicrobial susceptibility testing
MICs of b-lactams were determined using the agar dilution method on cation-adjusted Mueller-Hinton agar (BBL, Becton Dickinson, Sparks, MD, USA) using a Steer's Replicator TM that delivers 10 4 cfu/10 mL spot. We tested the following antibiotics: cefoxitin (Abraxis Pharmaceutical Products, Schaumburg, IL, USA), piperacillin (Sigma Chemical Co. Inc., Pearl River, NY, USA) were tested at a constant concentration of 4 mg/L in combination with cefepime, imipenem, meropenem, ertapenem and doripenem. For non-b-lactam antibiotics (e.g. aminoglycosides and quinolones), antimicrobial susceptibility testing was performed using the Microscan Autoscan System (Siemens, West Sacramento, CA, USA). Results were interpreted according to the CLSI criteria 31 except for doripenem, for which the FDA breakpoint for Enterobacteriaceae (i.e. 0.5 mg/L susceptible) was used. The following ATCC control strains were used: E. coli 25922, P. aeruginosa 27853 and K. pneumoniae 700603.
Analytical isoelectric focusing (aIEF)
aIEF was performed to identify and determine the pIs of b-lactamases expressed by the KPC-Kp isolates. Crude cell lysates were prepared using a previously described method.
32 Enzyme extracts were loaded onto 5% polyacrylamide gels containing ampholines ( pH range, 3.5-9.5; GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and electrophoresed using a Multiphor II apparatus (Amersham Biosciences, Piscataway, NJ, USA). Gels were focused at 48C with 8 W for 150 min. The detection of b-lactamases was performed by the addition of 1 mM nitrocefin (Becton Dickinson Biosciences, Cockeysville, MD, USA) onto the gel. The following purified b-lactamase enzymes prepared by our laboratory were used as controls: TEM-1 ( pI, 5.4), SHV-1 ( pI, 7.6), KPC-2 ( pI, 6.7) and CMY-2 ( pI, 9.0).
Clonal analysis by PFGE PFGE was performed as described previously.
33, 34 Whole chromosomal DNA in agarose was digested with SpeI (Sigma-Aldrich, St Louis, MO, USA) and the restriction fragments were separated in a CHEF DRII apparatus (Bio-Rad Laboratories, Hercules, CA, USA). After electrophoresis, the gels were stained with ethidium bromide, illuminated under UV light and photographed. Computerassisted (BioNumerics; Applied Maths, Kortrijk, Belgium) analysis of PFGE patterns was performed. The Dice correlation coefficient was used to analyse the similarity of the banding patterns. Strains with similarity coefficients of .80% were considered to belong to the same PFGE type (i.e. clonally related), while those with indistinguishable PFGE banding patterns (.97% similarity coefficient) were considered to be of the same subtype. 35 Clustering was based on the unweighted pair-group method with arithmetic averages. The tolerance position was 1%.
rep-PCR
Genomic similarity of KPC-Kp isolates was also investigated with the DiversiLab TM Strain Typing System (Bacterial BarCodes, bioMérieux). Genomic DNA was extracted using the UltraClean TM Microbial DNA Isolation Kit (Mo Bio Laboratories). Rep-PCR was performed using the DiversiLab Klebsiella Kit (Bacterial BarCodes). Results were interpreted with DiversiLab Web-Based Software using the Pearson correlation and the modified KullbackLeibler methods. In this study, clonally related isolates were defined as a 95% homology as recorded by software provided by the manufacturer.
Results
Molecular characterization of b-lactamase genes
As summarized in Table 1 , sequencing analysis revealed that 25 (59.5%) strains harboured bla KPC-2 and the remaining 17 (40.5%) carried bla KPC-3 . The majority of KPC-Kp strains also contained bla TEM-1 (38/42, 90.5%) and bla SHV-11 (40/42, 95.2%); bla SHV-12 was detected in 50.0% (21/42) of KPC-Kp isolates. In general, seven isolates contained other SHV variants (VA-368, bla SHV-5 and bla SHV-68 ; VA-373, VA-375 and VA-384, bla SHV-14 ; VA-391, bla SHV-77 ; VA-398, bla SHV-27 ; VA-417, bla SHV-26 ). The aIEF results were consistent with these findings, showing b-lactamase bands of pI 5.4 (TEM-1 enzyme), 6.7 (KPC-2,-3), 7.6 (SHV-11 enzyme) and 8.2 (SHV-12 enzyme) ( Table 1) . b-Lactamases migrating with pIs .8.2 were not detected. The average number of b-lactamases in KPC-Kp isolates was 3.5 (range 3 -5) ( Table 1) . We did not detect bla CTX-M , bla IMP , bla VIM , bla CMY-2-like , bla ACT-1 , bla P99 , bla PER-1 , bla PSE , bla FOX , bla MIR or bla DHA genes among the 42 KPC-Kp isolates (Table 1) .
Antimicrobial susceptibility tests
As shown in Table 2 , KPC-Kp isolates expressed high-level resistance to all non-carbapenem b-lactams (MIC 90 s 128 mg/L), except for three isolates (VA-237, VA-387 and VA-398) that were susceptible to cefepime (MICs of 8 mg/L).
MIC 50 /90 values of carbapenems were 4/64 mg/L for imipenem and meropenem, 4/32 mg/L for doripenem and 8/128 mg/L for ertapenem. Approximately two-thirds of the isolates tested were susceptible to imipenem and meropenem. All isolates were doripenem-resistant according to the US FDA breakpoints, while 57.1% were susceptible to imipenem, 61.9% to meropenem and 4.8% to ertapenem according to the CLSI criteria. The carbapenem MIC cut-off values able to accurately predict KPC production in these isolates were: imipenem, 2 mg/L; meropenem, 1 mg/L; ertapenem, 2 mg/L; and doripenem, 1 mg/L (Table 2) . Combining either of the b-lactamase inhibitors, Endimiani et al. 
PFGE
Using the Dice similarity coefficient to assess clonality by PFGE, we found that 32 KPC-Kp isolates belonged to the same genotype (type A), whereas the remaining 10 isolates showed ,80% similarity (Figure 1 ). Isolates of PFGE type A were detected in collections from all five institutions. Thirteen subtypes of type A were observed, of which subtypes A1, A4, A9 and A13 were the most common. Isolates with subtypes A1, A4 and A9 were detected at the MSMCNY, whereas isolates of subtype A13 were collected at CC, UHCMC and MSMCNY ( Figure 1) . Interestingly, type A contains K. pneumoniae isolates possessing either bla KPC-2 or bla KPC-3 genes. However, each subtype includes strains that uniformly possess only a single bla KPC gene type. For example, subtypes A13 and A9 possess bla KPC-2 , whereas subtypes A1 and A4 carry bla KPC-3 .
rep-PCR
As shown in Figure 2(a) , using the Pearson correlation, two KPC-Kp genotypes were present. The major genotype included 25 KPC-Kp isolates collected in all five institutions, whereas the second included five strains collected at the MSMCNY only. The two genotypes shared a genomic homology of 80% to 95%. In contrast, using the modified Kullback -Leibler method, only one major KPC-Kp clone (n¼ 34) was observed (Figure 2b ).
Discussion
The CDC estimates that K. pneumoniae is responsible for 8% of hospital-acquired infections and 3% of nosocomial outbreaks. 36 In endemic areas, such as New York City, it is reported that more than one-third of K. pneumoniae isolates possess bla KPC genes. 3 Therefore, the spread of KPC-Kp is a significant clinical and public health concern. 1, 2, 37, 38 In the present study, we analysed 42 KPC-Kp isolates recently collected in five institutions from a large geographic region to determine the number of b-lactamases that were expressed in the isolates and the genomic relatedness of them using both PFGE and rep-PCR.
Overall, four important findings emerged from our study: (i) contemporary KPC-Kp isolates possess a complex b-lactamase background (an average of 3.5 b-lactamase genes per isolate); (ii) clavulanate and tazobactam are unable to restore the activity of b-lactams against these isolates; (iii) there is evidence that KPC-Kp isolates from the five institutions in the Eastern USA are clonally related; and (iv) rep-PCR is a quick and reliable method to study KPC-Kp outbreaks. Complex b-lactamase background Survey studies are showing that the b-lactamase background of K. pneumoniae is becoming more complex. 39 -41 In our analysis, the bla KPC-2/3 carbapenemase genes detected among KPC-Kp were often accompanied by the bla TEM-1 and bla SHV-11 genes; the bla SHV-12 ESBL gene was also frequently found (50% of strains). This was previously observed by Essack et al. among bla KPC -negative K. pneumoniae isolates. 39 However, it should be noted that using a standard DNA sequencing analysis method, many of the bla SHV-12 -producing organisms would have been missed (during our study, 15 out of 21 bla SHV-12 -positive KPC-Kp were identified as bla SHV-11 -containing only; data not shown). While SHV-11 is a broad-spectrum b-lactamase (group 2b), SHV-12 is an ESBL able to confer resistance to all cephalosporins (group 2be). 42 Thus, finding an additional SHV ESBL might have important clinical and epidemiological relevance. It should be noted that SHV-12 is one of the most prominent ESBLs found in the Eastern USA. 43 Standard b-lactamase inhibitors were unable to lower the MICs of b-lactams for our clinical KPC-Kp isolates. However, in previous studies, clones expressing only the bla KPC gene showed MICs of b-lactam/ b-lactamase inhibitor combinations three or four dilutions lower than the antibiotic alone. 44, 45 Therefore, we could speculate that the additional b-lactamases (e.g. SHV and TEM types) expressed by KPC-Kp isolates could counteract the activity of the commercially used b-lactamase inhibitors. For similar reasons, the escalating number of b-lactamases could also contribute to the impaired ability of clinical laboratories to identify KPC-producing isolates. 21, 24, 25 It is interesting to observe that bla CTX-M genes were not detected in our KPC-Kp isolates. This is in agreement with the known relatively low prevalence of CTX-M ESBLs among K. pneumoniae isolates in the USA compared with Asia, Europe, Canada and South America. 46 To the best of our knowledge, KPC-Kp isolates possessing bla CTX-M genes have been detected only in China, Brazil and Puerto Rico. 13, 14, 17 It is also interesting to note that production of AmpC enzymes could be reasonably excluded on the basis of our molecular and aIEF results.
In vitro activity
The antimicrobial susceptibility testing results show that KPC-Kp isolates are frequently resistant to aminoglycosides and quinolones and extremely resistant to all non-carbapenem b-lactams (MIC 90 s 128 mg/L). In addition, combinations of cefepime or carbapenems with clavulanate or tazobactam are unable to lower significantly the MICs. Our data indicate that the complexity of the class A b-lactamase background limits the clinical efficacy of novel combinations of b-lactam/b-lactamase inhibitors using currently available clavulanate or tazobactam for treating infections caused by KPC-producers.
Our analysis also shows the limitations of our current CLSI breakpoints for imipenem and meropenem. Two-thirds of imipenem and meropenem MIC results for KPC-Kp strains were in the susceptible range, and 95% of ertapenem MIC results were resistant. Having some KPC-containing isolates that were 'missed' by an ertapenem screen is also disturbing as an important clinical predictor may be lost. Clinicians should be aware of these important limitations and, when necessary, request further testing.
Using the US FDA Enterobacteriaceae breakpoints, all isolates were doripenem-resistant. Thus, in our opinion, isolates of K. pneumoniae that exhibit imipenem, meropenem or doripenem MICs 1 mg/L or ertapenem MICs 2 mg/L should be screened by PCR for bla KPC genes or with a phenotypic method (i.e. modified Hodge test) for carbapenemase production. 25 It should be noted that 10 KPC-Kp isolates (24%) included in PFGE type A expressed high-level resistance to carbapenems (i.e. MICs of imipenem 32 mg/L). Since production of other common carbapenemases has been excluded by molecular analysis and aIEF, this result may be due to alterations of outer membrane proteins such as OmpK35, OmpK36 and OmpK37. 47, 48 Strains lacking OmpK35 and OmpK36 have been reported to occur frequently among KPC-Kp strains. 6, 17, 24, 44 Clonal analysis PFGE results show that 76% of KPC-Kp isolates were clonally related and were included in one common type (type A). Surprisingly, type A KPC-Kp was present in all five institutions studied. We also performed genotyping using rep-PCR. In our case, the modified Kullback -Leibler method of analysis of genotype data seemed to be more consistent than the Pearson correlation when compared with PFGE.
As in the case of Staphylococcus aureus, 49 clonal analysis of KPC-Kp isolates is important for understanding how these organisms may be responsible for outbreaks and how these isolates are spreading in our healthcare system. We demonstrated that the majority of KPC-Kp isolates that are spreading from institution to institution in the Eastern USA originated from a single K. pneumoniae clone. We also demonstrated that the DiversiLab TM Strain Typing System can be used to quickly analyse large numbers of K. pneumoniae isolates.
Conclusions
In summary, the above results show why K. pneumoniae containing bla KPC represent a formidable therapeutic, diagnostic and clinical challenge. The complex b-lactamase background contributes to the incapacity of current b-lactams and b-lactam/ b-lactamase inhibitor combinations to inhibit KPC-Kp strains. It is most concerning that a single clone may be contributing to the current outbreaks in the Eastern USA. Further studies are warranted to assess if these related isolates possess transferable resistance determinants in common (e.g. Tn4401, plasmids and the KQ element), which are important in the dissemination of the MDR phenotype in KPC-Kp. 50, 51 and R. A. B.) and the Geriatric Research Education and Clinical Care VISN 10 (R. A. B.).
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